SG11201405718QA - Anti-robo4-antibody - Google Patents

Anti-robo4-antibody

Info

Publication number: SG11201405718QA
Authority: SG; Singapore
Prior art keywords: robo4; antibody
Prior art date: 2012-04-27

Application number

SG11201405718QA

Inventor

Yoshitaka Isumi

Toshiyuki Sato

Jun Hasegawa

Tatsuya Inoue

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-27

Filing date

2013-04-26

Publication date

2014-10-30

2012-04-27 Priority claimed from JP2012103929A external-priority patent/JP2013230115A/en

2013-01-24 Priority claimed from JP2013011042A external-priority patent/JP2014141434A/en

2013-04-26 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2014-10-30 Publication of SG11201405718QA publication Critical patent/SG11201405718QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Hematology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Cell Biology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)

SG11201405718QA 2012-04-27 2013-04-26 Anti-robo4-antibody SG11201405718QA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2012103929A JP2013230115A (en)	2012-04-27	2012-04-27	Anti-robo4 antibody
JP2013011042A JP2014141434A (en)	2013-01-24	2013-01-24	Anti-robo4-antibody
PCT/IB2013/053312 WO2013160879A1 (en)	2012-04-27	2013-04-26	Anti-robo4-antibody

Publications (1)

Publication Number	Publication Date
SG11201405718QA true SG11201405718QA (en)	2014-10-30

Family

ID=48670623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201405718QA SG11201405718QA (en)	2012-04-27	2013-04-26	Anti-robo4-antibody

Country Status (23)

Country	Link
US (2)	US9683040B2 (en)
EP (1)	EP2841457B1 (en)
JP (2)	JP5897205B2 (en)
KR (2)	KR101950898B1 (en)
CN (1)	CN104768973B (en)
AU (1)	AU2013254313B2 (en)
BR (1)	BR112014026649A2 (en)
CA (1)	CA2868074A1 (en)
CO (1)	CO7111295A2 (en)
DK (1)	DK2841457T3 (en)
ES (1)	ES2733434T3 (en)
HK (1)	HK1207093A1 (en)
IN (1)	IN2014DN07799A (en)
MX (1)	MX356749B (en)
MY (1)	MY166821A (en)
NZ (1)	NZ629291A (en)
PH (1)	PH12014502382B1 (en)
PL (1)	PL2841457T3 (en)
RU (1)	RU2682451C2 (en)
SG (1)	SG11201405718QA (en)
TW (1)	TWI606065B (en)
WO (1)	WO2013160879A1 (en)
ZA (1)	ZA201406235B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201405718QA (en) *	2012-04-27	2014-10-30	Daiichi Sankyo Co Ltd	Anti-robo4-antibody
JP6878283B2 (en)	2015-09-24	2021-05-26	第一三共株式会社	Anti-GARP antibody
EP3527225A4 (en) *	2016-10-12	2020-06-10	Daiichi Sankyo Company, Limited	Composition containing anti-robo4 antibody and other agents
KR20210070643A (en)	2019-12-05	2021-06-15	김명배	self-developed wearable bridge
WO2023156437A1 (en)	2022-02-16	2023-08-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
CN117384290B (en) *	2023-12-11	2024-04-09	苏州因特药物研发有限公司	Human ROBO1 binding molecules and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1992020791A1 (en)	1990-07-10	1992-11-26	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DE69229477T2 (en)	1991-09-23	1999-12-09	Cambridge Antibody Technology Ltd., Melbourn	Methods for the production of humanized antibodies
DK1024191T3 (en)	1991-12-02	2008-12-08	Medical Res Council	Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
DE69333823T2 (en)	1992-03-24	2006-05-04	Cambridge Antibody Technology Ltd., Melbourn	METHOD FOR PRODUCING MEMBERS OF SPECIFIC BINDING SAVINGS
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
CA2177367A1 (en)	1993-12-03	1995-06-08	Andrew David Griffiths	Recombinant binding proteins and peptides
US6214388B1 (en)	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
US6972323B1 (en)	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
PT1914244E (en)	1999-04-09	2013-07-26	Kyowa Hakko Kirin Co Ltd	Method of modulating the activity of functional immune molecules
CA2953239A1 (en)	2000-10-06	2002-04-18	Kyowa Hakko Kirin Co., Ltd.	Antibody composition-producing cell
ATE360068T1 (en) *	2000-11-06	2007-05-15	Cancer Rec Tech Ltd	IMAGING PROCEDURES, DIAGNOSIS AND TREATMENT OF DISEASES
JP4583638B2 (en) *	2001-03-15	2010-11-17	独立行政法人科学技術振興機構	Acetyllysine-recognizing monoclonal antibody and method for producing the same
EP1534318A4 (en)	2002-06-27	2009-07-01	Univ Utah Res Found	Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
PT1565491E (en)	2002-11-20	2010-07-06	Cancer Rec Tech Ltd	Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis
NZ541458A (en)	2003-01-07	2006-04-28	Symphogen As	Method for manufacturing recombinant polyclonal proteins
KR20090089462A (en)	2006-12-11	2009-08-21	유니버시티 오브 유타 리써치 파운데이션	Compositions and methods for treating pathologic angiogenesis and vascular permeability
US7834154B2 (en)	2007-02-09	2010-11-16	Genentech, Inc.	Anti-ROBO4 antibodies and uses therefor
TWI480050B (en) *	2009-02-10	2015-04-11	Daiichi Sankyo Co Ltd	Anti-mst1r antibodies and uses thereof
SG11201405718QA (en) *	2012-04-27	2014-10-30	Daiichi Sankyo Co Ltd	Anti-robo4-antibody

2013
- 2013-04-26 SG SG11201405718QA patent/SG11201405718QA/en unknown
- 2013-04-26 ES ES13730645T patent/ES2733434T3/en active Active
- 2013-04-26 BR BR112014026649A patent/BR112014026649A2/en not_active Application Discontinuation
- 2013-04-26 IN IN7799DEN2014 patent/IN2014DN07799A/en unknown
- 2013-04-26 MY MYPI2014703067A patent/MY166821A/en unknown
- 2013-04-26 DK DK13730645.2T patent/DK2841457T3/en active
- 2013-04-26 EP EP13730645.2A patent/EP2841457B1/en active Active
- 2013-04-26 JP JP2015507659A patent/JP5897205B2/en active Active
- 2013-04-26 TW TW102115219A patent/TWI606065B/en not_active IP Right Cessation
- 2013-04-26 KR KR1020147029492A patent/KR101950898B1/en active IP Right Grant
- 2013-04-26 WO PCT/IB2013/053312 patent/WO2013160879A1/en active Application Filing
- 2013-04-26 KR KR1020197004552A patent/KR20190020838A/en not_active Application Discontinuation
- 2013-04-26 NZ NZ629291A patent/NZ629291A/en not_active IP Right Cessation
- 2013-04-26 CN CN201380019999.8A patent/CN104768973B/en not_active Expired - Fee Related
- 2013-04-26 MX MX2014012351A patent/MX356749B/en active IP Right Grant
- 2013-04-26 CA CA2868074A patent/CA2868074A1/en not_active Abandoned
- 2013-04-26 RU RU2014147616A patent/RU2682451C2/en not_active IP Right Cessation
- 2013-04-26 AU AU2013254313A patent/AU2013254313B2/en not_active Ceased
- 2013-04-26 US US14/397,210 patent/US9683040B2/en active Active
- 2013-04-26 PL PL13730645T patent/PL2841457T3/en unknown
2014
- 2014-08-25 ZA ZA2014/06235A patent/ZA201406235B/en unknown
- 2014-10-24 PH PH12014502382A patent/PH12014502382B1/en unknown
- 2014-10-27 CO CO14236457A patent/CO7111295A2/en unknown
2015
- 2015-08-10 HK HK15107712.5A patent/HK1207093A1/en not_active IP Right Cessation
- 2015-12-11 US US14/966,292 patent/US9562096B2/en active Active
2016
- 2016-03-01 JP JP2016038918A patent/JP6267733B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HK1207093A1 (en)	2016-01-22
TWI606065B (en)	2017-11-21
MX2014012351A (en)	2015-01-12
TW201348257A (en)	2013-12-01
EP2841457B1 (en)	2019-04-24
US9562096B2 (en)	2017-02-07
JP2016175893A (en)	2016-10-06
BR112014026649A2 (en)	2017-07-18
DK2841457T3 (en)	2019-07-22
CA2868074A1 (en)	2013-10-31
MX356749B (en)	2018-06-12
PH12014502382A1 (en)	2015-01-12
PH12014502382B1 (en)	2015-01-12
JP2015515490A (en)	2015-05-28
NZ629291A (en)	2016-09-30
RU2014147616A (en)	2016-06-20
CN104768973A (en)	2015-07-08
US20160108120A1 (en)	2016-04-21
RU2682451C2 (en)	2019-03-19
US20150098945A1 (en)	2015-04-09
KR20150008074A (en)	2015-01-21
ZA201406235B (en)	2016-07-27
AU2013254313A1 (en)	2014-09-18
IN2014DN07799A (en)	2015-05-15
WO2013160879A1 (en)	2013-10-31
AU2013254313B2 (en)	2017-03-30
JP6267733B2 (en)	2018-01-24
ES2733434T3 (en)	2019-11-29
US9683040B2 (en)	2017-06-20
PL2841457T3 (en)	2019-09-30
EP2841457A1 (en)	2015-03-04
KR101950898B1 (en)	2019-02-22
JP5897205B2 (en)	2016-03-30
KR20190020838A (en)	2019-03-04
MY166821A (en)	2018-07-23
CO7111295A2 (en)	2014-11-10
CN104768973B (en)	2019-01-22

Publication	Publication Date	Title
EP2935220A4 (en)	2016-04-27	Peri-carbinols
EP2920142A4 (en)	2016-08-10	Methanofullerenes
HK1204445A1 (en)	2015-11-20	Surrobody cojugates surrobody
ZA201406235B (en)	2016-07-27	Anti-robo4-antibody
EP2920157A4 (en)	2016-05-11	Di-macrocycles
EP2873363A4 (en)	2016-03-02	Diopsimeter
EP2834250A4 (en)	2015-10-14	Lithiumsilicate
GB201203307D0 (en)	2012-04-11	Remvox
GB201205346D0 (en)	2012-05-09	Loadwatch
GB201205515D0 (en)	2012-05-09	Shutterball
GB201205354D0 (en)	2012-05-09	Herbscan bookcradle
GB201205311D0 (en)	2012-05-09	InternalGCN
GB201204911D0 (en)	2012-05-02	Superswoosher
GB201204748D0 (en)	2012-05-02	Toretear
GB201204316D0 (en)	2012-04-25	Comniview
GB201204245D0 (en)	2012-04-25	MobiKey
GB201204164D0 (en)	2012-04-25	Plugstop
GB201204088D0 (en)	2012-04-18	Tidythatcable
GB201203777D0 (en)	2012-04-18	Quit-clip
GB201203776D0 (en)	2012-04-18	Sili-m8
GB201203844D0 (en)	2012-04-18	Salvacubo
GB201203808D0 (en)	2012-04-18	MicBooth
GB201203815D0 (en)	2012-04-18	Mini-meals
GB201203612D0 (en)	2012-04-18	Ishopfront
GB201203440D0 (en)	2012-04-11	Blu-seals